ENGLEWOOD, CO / ACCESSWIRE / March 19, 2019 / Aytu BioScience,...

ENGLEWOOD, CO / ACCESSWIRE / March 19, 2019 /
Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, announced two recent publications summarizing findings from the Phase 4, Natesto^® ''MY-T study.''
The MY-T study is the first clinical trial documenting that patients' hypogonadal symptoms improved after switching to Natesto from a topical testosterone gel. Further, the results confirmed the majority of patients prefer Natesto over topical testosterone gels and had higher levels of treatment satisfaction